Camrelizumab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Camrelizumab
- anti pd 1 monoclonal antibody shr 1210
- ANTI-PD-1 MONOCLONAL ANTIBODY SHR-1210
- apatinib combined with camrelizumab
- apatinib combined with shr 1210 injection
- bevacizumab and camrelizumab
- biological camrelizumab
- Biological: Camrelizumab
- camrelizumab
- Camrelizumab
- Camrelizumab (SHR-1210)
- camrelizumab [INN]
- Camrelizumab [WHO-DD]
- camrelizumab 200mg
- Camrelizumab 200mg
- camrelizumab and bevacizumab
- camrelizumab and cetuximab
- camrelizumab and decitabine
- camrelizumab famitinib
- camrelizumab fluzoparib
- camrelizumab for injection
- camrelizumab for Injection
- Camrelizumab for injection
- Camrelizumab for injection (200 mg, iv)
- camrelizumab for injection 200 mg iv
- camrelizumab gemcitabin cisplatin
And 53 more, listed on the interactive page.
- CAS registry numbers
- 1798286-48-2
- ChEMBL ID
- CHEMBL4297715
- FDA ingredient codes (UNII)
- 73096E137E
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- camrelizumab
- Type
- Antibody
- Drug name stem
- -mab; -mab
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Mechanism
- Programmed cell death protein 1 antagonist
- Action type
- Antagonist
- Target
- Programmed cell death protein 1
- Protein identifier
- Q15116
Open Targets mechanisms
- Mechanism
- Programmed cell death protein 1 antagonist
- Action type
- Antagonist
- Target
- Programmed cell death protein 1
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000294
- Subject identifier
- D001749
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000349
- Subject identifier
- D002292
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Osteosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000708
- Subject identifier
- D002294
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001061
- Subject identifier
- D002583
- Condition
- Lung Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001071
- Subject identifier
- D008175
And 44 more, listed on the interactive page.
- Condition identifier
- EFO_0000178
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Condition identifier
- EFO_0000199
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000294
- Condition identifier
- EFO_0000349
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000637
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000708
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001071
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002938
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003868
- Highest recorded phase
- 1
And 118 more, listed on the interactive page.
- Event
- abdominal infection
- Reports
- 3
- Reporting signal score
- 11.7002
- Event
- abdominal pain
- Reports
- 15
- Reporting signal score
- 14.4672
- Event
- acute graft versus host disease in intestine
- Reports
- 2
- Reporting signal score
- 7.81618
- Event
- acute graft versus host disease in liver
- Reports
- 2
- Reporting signal score
- 9.33056
- Event
- acute graft versus host disease in skin
- Reports
- 2
- Reporting signal score
- 6.29562
- Event
- adrenal insufficiency
- Reports
- 4
- Reporting signal score
- 9.32056
- Event
- alanine aminotransferase increased
- Reports
- 25
- Reporting signal score
- 57.462
- Event
- alopecia
- Reports
- 7
- Reporting signal score
- 6.72199
- Event
- anaemia
- Reports
- 38
- Reporting signal score
- 69.9507
- Event
- ascites
- Reports
- 6
- Reporting signal score
- 11.5164
- Event
- aspartate aminotransferase increased
- Reports
- 24
- Reporting signal score
- 56.8809
- Event
- blood bilirubin increased
- Reports
- 9
- Reporting signal score
- 19.6053
- Event
- blood creatinine increased
- Reports
- 7
- Reporting signal score
- 8.62888
- Event
- cardiotoxicity
- Reports
- 3
- Reporting signal score
- 6.90016
- Event
- cerebral radiation injury
- Reports
- 1
- Reporting signal score
- 7.873
- Event
- constipation
- Reports
- 12
- Reporting signal score
- 12.5097
- Event
- decreased appetite
- Reports
- 30
- Reporting signal score
- 58.0453
- Event
- dermatitis
- Reports
- 5
- Reporting signal score
- 11.7972
- Event
- diarrhoea
- Reports
- 39
- Reporting signal score
- 42.456
- Event
- disease progression
- Reports
- 9
- Reporting signal score
- 10.8563
- Event
- drug-induced liver injury
- Reports
- 6
- Reporting signal score
- 10.6525
- Event
- endocrine toxicity
- Reports
- 1
- Reporting signal score
- 6.48713
- Event
- fatigue
- Reports
- 34
- Reporting signal score
- 30.4141
- Event
- gastrointestinal disorder
- Reports
- 8
- Reporting signal score
- 12.6245
- Event
- gastrointestinal haemorrhage
- Reports
- 10
- Reporting signal score
- 13.9821
And 49 more, listed on the interactive page.
- NCT02721589
- NCT03171220
- NCT03182673
- NCT03871855
- NCT04282278
- NCT04346381
- NCT04832204
- NCT05214976
- NCT05429398
- NCT05605496
- NCT05699811
- NCT05799183
- NCT05809336
- NCT05941507
- NCT02738489
- NCT04331093
- NCT04593485
- NCT04979585
- NCT05051865
- NCT05512481
- NCT05789043
- NCT05983237
- NCT02742935
- NCT03394287
- NCT03945604
And 282 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (462)
- A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer
- A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
- A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
- A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
- A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
- A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
- A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
- A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
- A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
- A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
- A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
- A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
- A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
- A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
- A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
- A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
In development for (105)
- Acral lentiginous melanoma Phase 2
- Acute myeloid leukemia Phase 2
- Adenocarcinoma Phase 2
- Adrenal cortex carcinoma Phase 2
- Alveolar soft part sarcoma Phase 2
- Biliary tract cancer Phase 2
- Bone sarcoma Phase 2
- Breast cancer Phase 3
- Breast neoplasm Phase 3
- Cancer Phase 2
- Carcinoma of esophagus Phase 3
- Carcinosarcoma Phase 2
- Cervical adenocarcinoma Phase 2
- Cervical adenosquamous carcinoma Phase 2
- Cervical cancer Phase 2
- Cervical carcinoma Phase 2
- Cervical squamous cell carcinoma Phase 2
- Cholangiocarcinoma Phase 2
- Chordoma Phase 2
- Classic Hodgkin lymphoma Phase 3
Other linked conditions (3)
- Malignant epithelial tumor of ovary
- Ovarian carcinoma
- Ovarian clear cell cancer
Targets (1)
- PDCD1 Programmed cell death protein 1 antagonist